Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;64(12):2260-2269.
doi: 10.1111/trf.18041. Epub 2024 Nov 5.

Longitudinal outcomes of chronically transfused adults with sickle cell disease and a history of childhood stroke

Jennifer M Jones  1 , Julia Wool  2 , Elizabeth P Crowe  3 , Evan M Bloch  3 , Lydia H Pecker  2 , Sophie Lanzkron  4
Affiliations

Longitudinal outcomes of chronically transfused adults with sickle cell disease and a history of childhood stroke

Jennifer M Jones et al. Transfusion. 2024 Dec.

Abstract

Background: Many children with sickle cell disease (SCD) who suffer a stroke receive chronic transfusion therapy (CTT) indefinitely; however, their adulthood neurologic outcomes have not been reported. Understanding these outcomes is critical to inform decisions regarding curative therapy in childhood.

Study design and methods: In this retrospective study, we described a cohort of adults with SCD and a history of childhood stroke who received care at a single center and compared their outcomes with matched subjects without childhood stroke using chi2 and Mann-Whitney U tests.

Results: Of 42 subjects with childhood stroke, all received CTT for secondary stroke prophylaxis. Five (11%) developed recurrent stroke. The rate of stroke was similar in subjects with and without childhood stroke (0.7 vs. 1.1 per 100 person·years, p = .63). Both cohorts exhibited evidence of iron overload (median ferritin 2227 vs. 1409 ng/dL, p = .10) and alloimmunization (45% vs. 45%, p = 1.0), despite receiving care in a comprehensive SCD program.

Discussion: For adults with SCD who had a childhood stroke, our results suggest CTT returns the risk of stroke to that of age-matched stroke naïve patients with SCD.

Keywords: cerebrovascular accident; chronic red cell exchange transfusions; sickle cell disease; therapeutic apheresis.

PubMed Disclaimer

Conflict of interest statement

The authors have disclosed no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Prevalence of sickle cell disease (SCD) comorbidities in subjects with and without a history of childhood stroke. The prevalence of avascular necrosis (4 vs. 14, p = .01) and leg ulcers (0 vs. 6, p = .02) was lower in subjects with a history of childhood stroke as compared to subjects without. The prevalence of chronic kidney disease (Stage I or greater) trended lower in subjects with a history of childhood stroke (14 vs. 21, p = .13). Differences in the prevalence of other SCD comorbidities (retinopathy, acute chest syndrome, priapism, chronic kidney disease, elevated tricuspid jet velocity [TRJV]) between the cohorts were not observed.
See this image and copyright information in PMC

References

    1. Ohene‐Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288–294. - PubMed
    1. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11. - PubMed
    1. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769–2778. - PubMed
    1. Ware RE, Schultz WH, Yovetich N, Mortier NA, Alvarez O, Hilliard L, et al. Stroke with transfusions changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer. 2011;57(6):1011–1017. - PMC - PubMed
    1. Evidence‐based management of sickle cell disease: expert panel. 2014: 161.